Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 1,250 Shares of Stock
bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 1,250 shares of the stock in a transaction on Monday, August 28th. The shares were sold at an average price of $107.06, for a total transaction of $133,825.00. Following the completion of the sale, the insider now directly owns 28,555 shares in the company, valued at approximately $3,057,098.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 9.86% on Wednesday, reaching $112.50. 1,885,196 shares of the company’s stock traded hands. bluebird bio, Inc. has a 52 week low of $37.05 and a 52 week high of $123.75. The firm’s 50 day moving average is $95.59 and its 200 day moving average is $91.76. The firm’s market capitalization is $5.13 billion.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the prior year, the firm earned ($1.59) EPS. The company’s revenue for the quarter was up 977.4% compared to the same quarter last year. Analysts expect that bluebird bio, Inc. will post ($6.82) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its position in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock worth $556,918,000 after buying an additional 37,742 shares in the last quarter. Advisors Asset Management Inc. bought a new position in bluebird bio during the first quarter worth about $858,000. Winfield Associates Inc. raised its position in bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after buying an additional 162 shares in the last quarter. Macquarie Group Ltd. bought a new position in bluebird bio during the fourth quarter worth about $703,000. Finally, Alliancebernstein L.P. raised its position in bluebird bio by 50.1% in the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock worth $7,805,000 after buying an additional 28,640 shares in the last quarter.
Several research analysts recently commented on BLUE shares. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald set a $37.00 price target on shares of bluebird bio and gave the stock a “sell” rating in a research note on Monday, June 5th. Wedbush reaffirmed an “outperform” rating on shares of bluebird bio in a research note on Tuesday, June 6th. BTIG Research reaffirmed a “buy” rating and issued a $112.00 price target on shares of bluebird bio in a research note on Thursday, June 1st. Finally, Morgan Stanley raised their price target on shares of bluebird bio from $103.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. bluebird bio has an average rating of “Hold” and a consensus target price of $100.74.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.